$BENF

Beneficient (BENF): Unregistered Sales of Equity Securities

Beneficient (BENF) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false --03-31 0001775734 0001775734 2026-07-10 2026-07-10 0001775734 BENF:SharesOfClassCommonStockParValue0.001PerShareMember 2026-07-10 2026-07-10 0001775734 BENF:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockParValue0.001PerShareAndOneShareOfSeriesConvertibleP

Original reporting
Published Jul 13, 2026, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$BENF
Neutral
medium confidence
Mentioned
$BENF
Relevance
5/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BENFNeutralMed
01

Why it matters

The transaction introduces a resettable conversion price (monthly trailing VWAP with a 50% floor and no increase above the initial conversion price), plus an exchange cap on issuance unless stockholder approval is obtained.

02

Market read

Traders may reprice BENF’s dilution and conversion risk due to the resettable conversion price and the maximum Class A shares potentially issued upon conversion.

03

What to watch

Conversion is contingent on mandatory/optional triggers tied to reporting status and a five-year anniversary, so near-term dilution may be less immediate than the headline share count suggests.

Relevance 5/10Novelty 7/10Timing: filed after-hours on 2026-07-13, covering a July 10 closing of the primary capital transaction

Background

The 8-K reports Item 3.02 unregistered sales of equity securities and describes Series B-11 Resettable Convertible Preferred Stock issued in a primary capital transaction.

Company-level read

Ticker impact

$BENFNeutralMedium confidence
Context

Beneficient disclosed an unregistered issuance of 744,455 Series B-11 preferred shares convertible into Class A common stock at a resettable $3.6514 conversion price.

Expected impact

Near-term trading may hinge on how investors interpret the reset mechanics and potential dilution path; direction is uncertain without the transaction size/terms beyond the share count.

Evidence & confidence

This is a primary SEC 8-K disclosure of a new capital transaction structure (unregistered preferred issuance with conversion and monthly reset), which can affect dilution and conversion timing, but the article provides limited context on investor perception or immediate cash proceeds.

Market effects

Adds another example of structured convertible financing with reset features, relevant to how investors price capital raises in small-cap financial services/asset managers.

No clear regional spillover beyond Nasdaq-listed small caps.

Limited global relevance; primarily affects BENF’s capital structure and near-term trading dynamics.

Counterpoint

The reset conversion price includes a floor and a cap on conversion-driven issuance via an exchange cap, which may limit worst-case dilution versus a straight convertible.

Key entities

  • Beneficient

    Nasdaq-listed company filing the 8-K disclosing unregistered issuance of Series B-11 preferred convertible into Class A common stock.

  • Series B-11 Resettable Convertible Preferred Stock

    Convertible preferred with monthly reset conversion price mechanics and conversion into Class A common stock.

  • Customer (limited partner interest holder)

    The customer received 744,455 shares of Series B-11 preferred in exchange for a limited partner interest in an investment fund.

Related articles

$BENFMedAI 8/10

Beneficient Reports First Quarter Fiscal 2027 Results

Beneficient (NASDAQ: BENF) reported fiscal 2027 first-quarter results ended June 30, 2026. The company entered its first collateral management services engagement with a Texas state-chartered bank and closed primary capital commitments totaling over $16 million. Investments with fair value rose to $212.5 million. Operating expenses fell 84.3% to $12.5 million, including a $1.8 million loss-contingency accrual.

$BENFMed

Beneficient (BENF): Results of Operations and Financial Condition

Beneficient (BENF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q127earningsrelease.htm EX-99.1 Document For Immediate Release BENEFICIENT REPORTS FIRST QUARTER FISCAL 2027 RESULTS Company Enters into First Collateral Management Services Engagement, Closes More than $16 Million in Primary Capital Commitments Dallas, TX. – August 14,

$BENFMed

Beneficient Closes $7.44 Million GP Primary Capital Transaction

Beneficient (NASDAQ: BENF) said it closed a $7.44 million GP primary capital transaction with Quartus AI Fund II LP, managed by Quartus Capital Partners. As consideration, the fund received about $7.44 million of Beneficient resettable convertible preferred stock convertible into Class A common. The deal may add about $7.44 million to ExAlt loan collateral and tangible book value.

$BENFMed

Beneficient Reports Fourth Quarter & Fiscal Year Ended March 31, 2026 Results

Beneficient (NASDAQ: BENF) reported fiscal 2026 results for the year ended March 31, 2026, including a fourth-quarter increase in operating expenses to $17.5M (vs. $14.3M) tied to $3.1M non-cash impairment and a $62.8M loss contingency for the year. The company said it resolved GWG Holdings litigation, regained Nasdaq compliance, generated $51.5M gross proceeds from asset sales, and paid off HH-BDH Credit Agreement principal. It also named James Silk CEO and announced a first collateral manageme

$BENFMed

Beneficient (BENF): Results of Operations and Financial Condition

Beneficient (BENF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q426earningsrelease.htm EX-99.1 Document For Immediate Release Exhibit 99.1 BENEFICIENT REPORTS FOURTH QUARTER & FISCAL YEAR ENDED MARCH 31, 2026 RESULTS Transformative Fiscal 2026 Focused on Addressing Legacy Issues While Strengthening Foundation of the Company Benefic